DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Ssu-Chuan LaiYu-Ting SuChing-Chi ChiYung-Che KuoKam-Fai LeeYu-Chih WuPei-Chi LanMuh-Hwa YangTe-Sheng ChangYen-Hua HuangPublished in: Journal of experimental & clinical cancer research : CR (2019)
The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. The p-STAT3 activation increases the DNMT3b/OCT4 which confers the tumor early recurrence and poor prognosis of HCC patients. Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- dna methylation
- optical coherence tomography
- ejection fraction
- chronic kidney disease
- newly diagnosed
- diabetic retinopathy
- prognostic factors
- peritoneal dialysis
- emergency department
- epithelial mesenchymal transition
- gene expression
- patient reported outcomes
- optic nerve
- drug induced
- squamous cell